From VOA Learning English, this is the Health & Lifestyle report.
When the coronavirus pandemic was declared six months ago, international health experts were worried about people in Africa. Many feared the virus would cause great suffering across the continent.
The company Johnson & Johnson has begun the final part of its trial of a single-treatment, COVID-19 vaccine. The study will be one of the world's largest, testing the injection in 60,000 volunteers in the United States, South Africa, Argentina, Brazi
Health officials around the world are concerned about rising numbers of new coronavirus cases. But another highly infectious virus will soon be returning to Earth's Northern Hemisphere. That virus is influenza, commonly called the flu.
From VOA Learning English, this is the Health & Lifestyle report.
The future may mean more dengue and less malaria in parts of Africa if the planet continues to warm, a new study says.
The leader of drug maker Moderna says the company should know in November whether its experimental COVID-19 vaccine works.
A new public opinion study finds that the coronavirus health crisis has affected the mental health of young Americans under age 35.
A U.S. government study has found that vaping rates among young students fell sharply this year. The drop comes after last year's sudden increase in vaping-related illnesses and deaths.
Drug-maker AstraZeneca has temporarily suspended its COVID-19 vaccine tests after an "unexplained illness" in a person who took the treatment.
Nine leading American and European drug-makers promised to follow scientific standards in the race to develop an effective coronavirus vaccine.
From VOA Learning English, this is the Health & Lifestyle report.
Modified common cold viruses are being used to create COVID-19 vaccine candidates in China and Russia. Such viruses have been studied for over 30 years, but are still not widely used. They are now driving the vaccine research from Russia's Gamaleya Insti
Modified common cold viruses are being used to create COVID-19 vaccine candidates in China and Russia. Such viruses have been studied for over 30 years, but are still not widely used. They are now driving the vaccine research from Russia's Gamaleya Insti
Modified common cold viruses are being used to create COVID-19 vaccine candidates in China and Russia. Such viruses have been studied for over 30 years, but are still not widely used. They are now driving the vaccine research from Russia's Gamaleya Insti
Modified common cold viruses are being used to create COVID-19 vaccine candidates in China and Russia. Such viruses have been studied for over 30 years, but are still not widely used. They are now driving the vaccine research from Russia's Gamaleya Insti
Modified common cold viruses are being used to create COVID-19 vaccine candidates in China and Russia. Such viruses have been studied for over 30 years, but are still not widely used. They are now driving the vaccine research from Russia's Gamaleya Insti
Modified common cold viruses are being used to create COVID-19 vaccine candidates in China and Russia. Such viruses have been studied for over 30 years, but are still not widely used. They are now driving the vaccine research from Russia's Gamaleya Insti
Modified common cold viruses are being used to create COVID-19 vaccine candidates in China and Russia. Such viruses have been studied for over 30 years, but are still not widely used. They are now driving the vaccine research from Russia's Gamaleya Insti
Modified common cold viruses are being used to create COVID-19 vaccine candidates in China and Russia. Such viruses have been studied for over 30 years, but are still not widely used. They are now driving the vaccine research from Russia's Gamaleya Insti
Modified common cold viruses are being used to create COVID-19 vaccine candidates in China and Russia. Such viruses have been studied for over 30 years, but are still not widely used. They are now driving the vaccine research from Russia's Gamaleya Insti
The U.S. federal government has told health officials in all 50 states to be ready for a coronavirus vaccine by November 1.
The World Health Organization (WHO) says COVID-19 has interfered with necessary health services in almost every country. It says low- and middle-income nations are affected the most by the crisis.
Researchers say antibodies, made by the human body to fight the new coronavirus, could last for at least four months. Earlier reports suggested that these special proteins disappeared quickly.